EANS-Adhoc: Marseille-Kliniken AG / - Increase in turnover in the first three quarters of 2008/2009 to EUR 174.3 million - Turnaround in the start-up costs of the expansion facilities completed - N

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

quarterly report

08.05.2009

Berlin, 8th May 2009. Marseille-Kliniken AG (Prime Standard, ISIN DE
0007783003, MKA) was able to increase its operating turnover in the
first three months of the financial year 2008/2009 (1st July 2008 -
31st March 2009) by 2.1 % to EUR 174.3 million (previous year: EUR
170.6 million). The group net income after minority interest
decreased from EUR 10.4 million to EUR -3.0 million, whereas special
items of EUR 11.9 million were included in the previous year´s value.
With this, the result per share decreased to EUR -0.24, from EUR 0.86
the previous year. The EBIT/IFRS amounted to EUR 1.4 million,
compared to EUR 12.6 million including special items the previous
year. The EBITDAR/IFRS amounted to EUR 43.1 million in comparison
with EUR 51.0 million the previous year. The balanced equity
decreased from EUR 82.2 to EUR 76.0 million. The equity ratio
increased from 32.6 % to 33.7 %, while the net debt was reduced from
EUR 69.8 million in the previous year to EUR 68.7 million for the
current year.

The decline in the group returns to EUR -3.0 million is based largely
on an extraordinary income of EUR 6.9 million in the previous year
from the sale of property as well as from a latent tax rebate claim
of EUR 4.9 million. Minus these special items the comparable return
in the previous year, including the start-up costs for new
facilities, amounted to EUR -1.5 million. In comparison with the
previous year, increased expenditure on energy and maintenance as
well as ongoing amortisation on intangible assets had a negative
impact in this reporting period.

The group result, adjusted in accordance with DVFA/SG (IFRS),
decreased to EUR 5.5 million from EUR 6.7 million in the previous
year. This corresponds to EUR 0.46 per share for this reporting
period in comparison to EUR 0.55 per share in the previous year. In
particular, increased costs for energy and maintenance as well as
ongoing amortisation on intangible assets were responsible for this.
The adjusted EBITDAR of EUR 45.1 million differed only slightly from
the previous year´s figure of EUR 44.8 million. The adjusted EBIT
amounted to EUR 9.0 million in comparison with EUR 11.6 million the
previous year. The capacity utilisation was able to be maintained at
a consistently high level with the increased capacity of 186 beds.
The capacity utilisation rate maintained for the group´s 9,085 beds
was 92.5 % compared with the previous year´s figure of 92.5 % of
8,899 beds. The after-tax adjustments of EUR 7.2 million (previous
year: EUR 8.0 million) are based primarily on start-up costs for
seven care facilities that currently have 728 beds (8.0 % of the
group´s capacity) as well as four sites currently not in use and the
development of the acute care section which has been started in the
middle of 2008. The occupancy rate for the expansion facilities
increased in the course of the financial year from 47 % in the first
quarter to 58 % in the third quarter. In April the occupancy rate was
61.5 %.

The capacity in the care area increased from 7,616 beds to 7,756 beds
on the reporting day. Turnover in this segment grew from EUR 132.7
million in the previous year to EUR 134.5 million for this reporting
period. The same costs that negatively affected the group´s returns
also had an adverse effect on the result according to DVFA/SG (IFRS)
of EUR 4.4 million (previous year: EUR 5.9 million). The capacity
utilisation rate in the care section amounted to 92.4 % (in
comparison with 93.4 % for the previous year) with the addition of
the Düsseldorf and Potsdam sites to the stock of facilities.

In the rehabilitative care section, capacity was increased from 1,283
beds to 1,329 beds. Turnover increased from EUR 37.9 million in the
previous year to EUR 39.8 million in the current reporting period.
The result according to DVFA/SG (IFRS) increased by EUR 0.8 million
to EUR 1.1 million, confirming an already long-term trend. The
capacity utilisation rate in the sector increased from 89.2 % to 92.7
%.

Marseille-Kliniken AG continues to show resistance to the current
economic depression. The current economic crisis is therefore having
no direct consequences for the company. On the contrary, the
management are expecting a continuation in growth given the high
level of predictability in business development. In the area of care,
a further increase in occupancy along with a simultaneous drop in
starting losses in the fourth quarter is being anticipated. In
addition, first savings should be made in the current financial year
through cost-reducing measures of EUR 3.0 million which will achieve
full effect in the next financial year. In the area of rehabilitative
car, positive results are expected for the whole financial year given
the stable capacity utilisation level of over 90 %.

Also in the expansion facilities the currently high level of
competition in the care sector is becoming noticeable. As a result,
the increase in occupancy originally planned for the financial year
will not be realised at the anticipated speed. In addition, since the
facilities in Oberhausen and Waldkirch are no longer going into
operation in this financial year, an adjustment of the turnover
prognosis to between EUR 236.0 million and EUR 238.0 million is
necessary. As a result, the EBIT returns of 7 % forecast for the
financial year 2008/2009 will not be reached. Instead, the board of
directors anticipates an EBIT of EUR 5.0 million. The EBIT after
adjustments of costs of expansion and idleness will aggregate to
approximately EUR 13.0 Mio. The company expects a positive after-tax
result for the whole financial year. After the completion of the
expansion activities the company assumes a sustained EBIT return of 7
% for the next financial year.

For more detailed information, please visit the website
www.marseille-kliniken.com to read the quarterly report.

End of ad hoc release

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marseille-Kliniken AG

Axel Hölzer

CEO

Alte Jakobstraße 79/80

10709 Berlin

Germany

Tel.: +49 30 / 246 32-400

Fax: +49 30 / 246 32-401

www.marseille-kliniken.com

Hillermann Consulting

Christian Hillermann

Investor Relations for Marseille-Kliniken AG

Poststraße 14/16

20354 Hamburg

Germany

Tel.: +49 40 / 320 279 10

Fax: +49 40 / 320 279 114

www.hillermann-consulting.de

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / regulated dealing